Evaxion Biotech A/S Adr (EVAX) has released an update.
Evaxion Biotech A/S has announced successful animal studies for their EVX-B1 vaccine candidate targeting Staphylococcus aureus, showing significant reduction in disease burden. With no current S. aureus vaccines for human use, and a rising threat of antibiotic-resistant strains, Evaxion’s AI-Immunology-powered vaccine shows promise for future human clinical trials. This breakthrough could address the critical need for effective treatments against infections that cause severe health issues and even death.
For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.
